NORAMID SE · A Novel Rapid Nucleic Acid Isolation Microchip Intergrated in the FASTGENE PCR Microfluidics Device for Point of Care Diagnosis of Infectious Diseases
„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“
- Период
- 2021-12-01 → 2023-11-30
- Финансиране от ЕС
- 196 708 €
- Участници
- 1
- Схема
- MSCA-IF
Линиите свързват координатора с партньорите.
Накратко на български
Разработва се нов микрочип за бързото отделяне на генетичен материал от патогени, който ще се интегрира в устройството FASTGENE за диагностика на инфекции като COVID-19. Това ще позволи по-бързо и точно откриване на вируси дори при ниско тяхно количество в пробата.
Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.
Резултати накратко
A Novel Rapid Nucleic Acid Isolation Microchip Intergrated in the FASTGENE PCR Microfluidics Device for Point of Care Diagnosis of Infectious Diseases
Infectious diseases are a major challenge to global health. With the emergence of disease outbreak such as coronavirus (covid-19) which is a global pandemic, there is need for early and prompt diagnosis for the effective management of infectious diseases. Conventional polymerase chain reaction (PCR) based devices that detect microbial nucleic acids are the most sensitive, specific and reliable diagnosis tools for microbial pathogens but are time-consuming and requires expertise making them not suitable for Point of Care (POC) diagnosis. More so, nucleic acid extraction is primary to PCR detection of pathogens but most nucleic acid extraction methods are labour-intensive and time consuming, limiting the prompt detection of infectious pathogens. Recently, BforCure developed an ultrafast, sensitive and small-volume (25 µl) real-time PCR system based on microfluidic thermalization known as FASTGENE technology device to molecularly detect bacterial and viral pathogens including covid-19 directly from nasal swap samples and maintains a good thermal homogeneity throughout the reaction to ensure the best PCR efficiency and specificity. However, one of the challenges of this device is that it is less sensitive to detect viruses when the viral load is low since it directly amplify samples without extraction of nucleic acid for optimal detection. Recent reports suggest that microfluidic-based nucleic acid device can speed up nucleic acid isolation from pathogens. Hence,the aim of this project is to develop a simple, rapid and cost-effective novel NA isolation microchip and integrate it in the FASTGENE quantitative PCR device by BforCure for POC diagnosis of infectious diseases.
Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз
Цел на проекта
The catastrophic impact of infectious diseases including the recent coronavirus (covid-19) pandemic on global health cannot be over emphasized. Polymerase chain reaction (PCR) based techniques are the most sensitive and reliable diagnostic tools for infectious diseases but are time-consuming and labour-intensive. This project aims to develop a simple, rapid and cost-effective novel nucleic acid (NA) isolation microchip and integrate it in the FASTGENE PCR microfluidics device for point of care (POC) diagnosis of infectious diseases. The project will exploit the competence of the experience researcher (ER) on the theoretical and practical knowledge of medical biotechnology and molecular epidemiology while implementing the expertise of BforCure team in microfluidics design to develop this new microchip. The ER will develop a new NA isolation microchip based on silica gel solid phase extraction system and integrate it in the FASTGENE PCR microfluidics device of BforCure to become a closed system device that automatically extracts NA and amplifies it to detect infectious diseases. After the design and production, the device will be tested for its efficiency. Once satisfied, positive control bacteria and viral samples will be used to assess the performance of the device and the results will be compared with that of standard commercially available NA extraction and PCR kits. The device is expected to have high sensitive compared to other microfluidics devices, reliable and can detect pathogens in less than 20 minutes. A patent will be secured for the product while the findings of the research will be made public and commercialized. This novel device will be suitable for POC diagnosis to promptly detect and manage infectious diseases. This project will develop the ER’s potential to transform research ideas to products and build up his industrial experience. It will make the ER gain expertise in the design and fabrication of microfluidics tools and develop his entrepreneuri
Оригинален текст от CORDIS (на английски).
Участници
- BFORCURE · MONTREUILКоординаторФранция
Връзки
Данни: CORDIS, © Европейски съюз